Human PIK3CA Gene Mutation Detection Kit
Brochure Download
Fill out the form to download
PIK3CA Gene Mutation Detection Kit is a PCR-based in vitro diagnostic test designed to detect 5 types of human PIK3CA gene mutations in exons 9 and 20 from tumor DNA specimens of paraffin-embedded section and provide reference for personalized medicine of clinicians.
Product Features:
- High Sensitivity: accurately detect 1% of mutant DNA from 10ng of the wild-type gene
- High Specificity: effectively improve the testing specificity by ARMS-PCR detection technology
- High Accuracy: closed tube reaction effectively prevent false negative and false positive results through the standard internal system and UNG enzyme system
- Quick & Easy: easy to operate with reliable results analysis, 90 mins to complete
Product Information
| Cat.No. | Product Name | Technology | Specification | Supply Format |
| YZYMT-020 | Human PIK3CA Gene Mutation Detection Kit | PCR-Fluorescence Method | 12tests/ kit | CE-IVD/RUO |
Clinical Significance
PIK3CA gene encodes phosphatidylinositol-3-kinase p110α catalytic subunit, which is expressed in normal human brain, lung, breast, gastrointestinal tract, cervix, ovary and other tissues. Together with RAS signaling pathway, PIK3CA and RAS signaling pathway constitute two parallel pathways downstream of EGFR, which have important physiological functions such as regulating cell proliferation, survival, death and differentiation. The mutation rate of this gene is 26% in breast cancer, 25% in colorectal cancer, and 2% in lung cancer. The mutation sites are mainly located in exon 9 and exon 20.
PIK3CA gene mutation status directly or indirectly affects the medication and prognosis of colorectal cancer, breast cancer, lung cancer and other cancers. Studies have found that patients with PIK3CA mutation in the PI3K/AKT pathway have a poor response to trastuzumab. Another study showed that colorectal cancer patients with PIK3CA mutation were resistant to cetuximab. In addition, 2% of patients with lung cancer have concomitant PIK3CA mutations, which are associated with resistance to Tkis. Therefore, detection of PIK3CA mutation status can effectively guide the individualized treatment of breast cancer and colorectal cancer patients.
Clinical studies have confirmed that detection of PIK3CA gene mutation status can predict the response rate of cetuximab treatment in patients with metastatic colorectal cancer, and can also be used as a molecular marker for predicting the efficacy of aspirin adjuvant therapy in colorectal cancer.
PIK3CA Gene Mutation Type Detected by the Kit
| Exon | Mutation Type | Base Change | Mutation Rate |
| 9 | E542K | GAA>AAA | 16.2% |
| E545K | GAG>AAG | 24.1% | |
| E545D | GAG>GAT | 0.6% | |
| 20 | H1047R | CAT>CGT | 53.4% |
| H1047L | CAT>CTT |
